AI is expediting the timeline and personalization of solid tumor drug development using multi-omics, imaging, and advanced computational models.
Key Details
- 1AI integration with multi-omics and spatial transcriptomics data accelerates drug target discovery and validation, reducing R&D cycles from ~10 to 2-3 years.
- 2Imaging data (CT) and electronic health records are utilized in AI-powered patient-specific screening and drug prioritization.
- 3Generative AI platforms optimize small molecules, biologics, and mRNA vaccines; for example, inhibitors for historically 'undruggable' targets like KRAS were rapidly designed.
- 4AI models improve efficacy, predict resistance, and optimize pharmacokinetics with significant reductions in time and resource usage.
- 5Clinical translation faces challenges such as data bias, model transparency, and real-world validation gaps.
- 6Recent advances include AI-driven antibody-drug conjugate design and mRNA vaccine optimization.
Why It Matters
This overview underscores how imaging data and AI collaboration are transforming oncology research and clinical practices, promising faster delivery of targeted therapies. Addressing the ongoing challenges in data equity, model transparency and validation will be crucial for successful clinical impact.
Source
EurekAlert
Related News
•EurekAlert
AI Advances in Radiology and Multimodal Integration for IBD Management
A major review details how AI supports radiological and multimodal integration in inflammatory bowel disease (IBD) management, highlighting current applications and future challenges.
•EurekAlert
Foundation Models Advance Ophthalmic Imaging AI: Review Highlights Milestones and Challenges
A systematic review evaluates five cutting-edge ophthalmic AI foundation models, highlighting their technical evolution and clinical trial evidence.
•EurekAlert
Deep Learning Enhances Bionic Eye Communication with Brain
Researchers show that AI can optimize stimulation patterns in brain-implanted visual prostheses to improve perceived vision in blind individuals.